ARTICLE | Financial News

PCORI approves $83M for 26 CER studies

September 30, 2015 1:05 AM UTC

The Patient-Centered Outcomes Research Institute approved awards totaling $83 million to fund 26 comparative clinical effectiveness research studies.

PCORI said two awards totaling $29.5 million will fund studies of HCV care. PCORI spokesperson Christine Stencel told BioCentury the PCORI-funded PRIORITIZE study will compare effectiveness and side effects in HCV genotype 1 patients treated with Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), Viekira Pak from AbbVie Inc. (NYSE:ABBV) and grazoprevir/elbasvir ( MK-5172/ MK-8742) from Merck & Co. Inc. (NYSE:MRK). The study will also evaluate treatment adherence, out-of-pocket costs and other patient outcomes. ...